Cargando…
Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication‐induced (medication‐overuse) headache, it is the third‐leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up...
Autores principales: | Pellesi, Lanfranco, Guerzoni, Simona, Pini, Luigi Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697612/ https://www.ncbi.nlm.nih.gov/pubmed/28409893 http://dx.doi.org/10.1002/cpdd.345 |
Ejemplares similares
-
Clinical Evidence of Cannabinoids in Migraine: A Narrative Review
por: Lo Castro, Flavia, et al.
Publicado: (2022) -
Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand?
por: Pellesi, Lanfranco
Publicado: (2023) -
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
por: Guerzoni, Simona, et al.
Publicado: (2016) -
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017) -
Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017)